Go to:
Logótipo
Comuta visibilidade da coluna esquerda
Você está em: Start > Publications > View > The International System for Reporting Serous Fluid Cytopathology: How to Incorporate Molecular Data in Cytopathology Reports
Publication

Publications

The International System for Reporting Serous Fluid Cytopathology: How to Incorporate Molecular Data in Cytopathology Reports

Title
The International System for Reporting Serous Fluid Cytopathology: How to Incorporate Molecular Data in Cytopathology Reports
Type
Article in International Scientific Journal
Year
2021
Authors
Pinto, D
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Chandra, A
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Fernando Schmitt
(Author)
FMUP
View Personal Page You do not have permissions to view the institutional email. Search for Participant Publications View Authenticus page View ORCID page
Journal
The Journal is awaiting validation by the Administrative Services.
Vol. 74
Pages: 66-76
ISSN: 2673-5261
Other information
Authenticus ID: P-00T-WK6
Abstract (EN): <jats:p>Serous effusion cytology is widely employed in the initial evaluation of the etiology of effusions with a high diagnostic sensitivity. To standardize practices, The International System for Reporting Serous Fluid Cytology (TIS) was developed following best international practices, the most up-to-date literature, and expert consensus. In the context of this system, ancillary techniques play an important role. Besides defining basic principles in laboratory specimen handling, adequacy criteria, and a standardized reporting terminology with five diagnostic categories, TIS provides an actionable framework for using immunohistochemical and molecular testing in effusion samples, namely, in atypical, suspicious of malignant samples. For diagnostic purposes, these tests may be employed to distinguish between a primary and secondary neoplasm, to confirm a diagnosis of malignant mesothelioma vs. reactive mesothelial hyperplasia, and to correctly classify and determine the primary location of a metastasis. Theranostic molecular tests may also be used for these samples to evaluate potential therapeutic targets. Pathologists play a central role in guiding this process by determining adequacy and selecting appropriate ancillary tests. The activity in this area of research should increase in the near future as new therapeutic targets are discovered and new drugs enter the clinical practice.</jats:p>
Language: English
Type (Professor's evaluation): Scientific
Documents
We could not find any documents associated to the publication.
Related Publications

Of the same authors

The international system for reporting serous fluid cytopathology-diagnostic categories and clinical management (2020)
Article in International Scientific Journal
Pinto, D; Chandra, A; Crothers, BA; Kurtycz, DFI; Fernando Schmitt

Of the same journal

The Multifaceted Profile of Thyroid Disease in the Background of DICER1 Germline and Somatic Mutations: Then, Now and Future Perspectives (2022)
Article in International Scientific Journal
Canberk S.; Correia M.; Lima A.R.; Bongiovanni M.; Sobrinho-Simões M; Soares, P; Maximo, V
Optimal Assessment of Metastatic Breast Carcinoma: The Value of Cytopathology Combined with Molecular Analysis (2022)
Article in International Scientific Journal
Souza da Silva, R; Fernando Schmitt
A Real-World Study Reporting the Use of Foundation Medicine® Testing in Portugal (2023)
Article in International Scientific Journal
Pinto, R; Fernando Schmitt
Recommend this page Top
Copyright 1996-2025 © Faculdade de Direito da Universidade do Porto  I Terms and Conditions  I Acessibility  I Index A-Z
Page created on: 2025-07-09 at 05:41:08 | Privacy Policy | Personal Data Protection Policy | Whistleblowing